Role of calcium channel blocking agents in the treatment of allergic asthma.
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001491:Basophils / Q000502:physiology; D001985:Bronchial Provocation Tests; D001986:Bronchial Spasm / Q000188:drug therapy / Q000503:physiopathology; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D006168:Guinea Pigs; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008407:Mast Cells / Q000502:physiology; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000503:physiopathology; D009543:Nifedipine / Q000494:pharmacology / Q000627:therapeutic use; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D051381:Rats; D012129:Respiratory Function Tests; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil; D009543:Nifedipine; D002118:Calcium